Known targets — ChEMBL curated mechanism
PDE10APDE3APDE4APDE4BPDE4CPDE4DPDE5A
The experimentally established mechanism targets of Ibudilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 7/20 | 1.00 |
| ▸ | PDE5A known ✓ | O76074 | 6/20 | 1.00 |
| ▸ | PDE3A known ✓ | Q14432 | 4/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 1.00 |
| ▸ | MIF | P14174 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibudilast SCHEMBL30390 | 1.00 | PDE4B (1.00) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL1123689 | 0.97 | PDE4B (0.94) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL1123688 | 0.97 | PDE4B (0.94) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| Ibudilast SCHEMBL1123710 | 0.93 | PDE4B (0.87) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL3203334 | 0.90 | PDE4B (0.81) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL653193 | 0.88 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL7506891 | 0.88 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL652912 | 0.88 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL10033623 | 0.88 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 | |
| SCHEMBL652753 | 0.88 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030301-A1 | COMBINATION OF IBUDILAST AND RILUZOLE AND METHODS OF USING SAME | MEDICINOVA, INC. (US) | 2020-01-30 | — | — | US | disclosed |
| EP-2892518-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | Pharnext (FR) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037416-A2 | NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE | PHARNEXT (FR) | 2014-03-13 | — | — | WO | disclosed |
| EP-2089028-A2 | METHOD FOR TREATING DELIRIUM | Avigen, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2026804-A1 | IBUDILAST FOR INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) ACTIVITY | Avigen, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008057496-A2 | METHOD FOR TREATING DELIRIUM | AVIGEN, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007142924-A1 | IBUDILAST FOR INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) ACTIVITY | AVIGEN, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030301-A1 | COMBINATION OF IBUDILAST AND RILUZOLE AND METHODS OF USING SAME | UCHL1, PRNP, TDP2 | PDE4B 638/4885PDE5A 93/4885PDE3A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.